196 related articles for article (PubMed ID: 11022835)
1. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome.
Lu CL; Chen CY; Chang FY; Chang SS; Kang LJ; Lu RH; Lee SD
J Gastroenterol Hepatol; 2000 Aug; 15(8):925-30. PubMed ID: 11022835
[TBL] [Abstract][Full Text] [Related]
2. Mebeverine alters small bowel motility in irritable bowel syndrome.
Evans PR; Bak YT; Kellow JE
Aliment Pharmacol Ther; 1996 Oct; 10(5):787-93. PubMed ID: 8899088
[TBL] [Abstract][Full Text] [Related]
3. Role of antispasmodics in the treatment of irritable bowel syndrome.
Annaházi A; Róka R; Rosztóczy A; Wittmann T
World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726
[TBL] [Abstract][Full Text] [Related]
4. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome].
Wittmann T; Fehér A; Rosztóczy A; Jánosi J
Orv Hetil; 1999 Feb; 140(9):469-73. PubMed ID: 10204402
[TBL] [Abstract][Full Text] [Related]
7. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome.
Van Outryve M; Mayeur S; Meeus MA; Rosillon D; Hendrickx B; Ceuppens M
J Clin Pharm Ther; 1995 Oct; 20(5):277-82. PubMed ID: 8576295
[TBL] [Abstract][Full Text] [Related]
8. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
Kennedy TM; Chalder T; McCrone P; Darnley S; Knapp M; Jones RH; Wessely S
Health Technol Assess; 2006 Jun; 10(19):iii-iv, ix-x, 1-67. PubMed ID: 16729918
[TBL] [Abstract][Full Text] [Related]
9. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
10. Effect of pinaverium bromide on jejunal motility and colonic transit time in healthy humans.
Bouchoucha M; Salles JP; Fallet M; Frileux P; Cugnenc PH; Barbier JP
Biomed Pharmacother; 1992; 46(4):161-5. PubMed ID: 1421047
[TBL] [Abstract][Full Text] [Related]
11. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.
Awad RA; Cordova VH; Dibildox M; Santiago R; Camacho S
Acta Gastroenterol Latinoam; 1997; 27(4):247-51. PubMed ID: 9401097
[TBL] [Abstract][Full Text] [Related]
12. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
[TBL] [Abstract][Full Text] [Related]
13. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study.
Chapman ND; Grillage MG; Mazumder R; Atkinson SN
Br J Clin Pract; 1990 Nov; 44(11):461-6. PubMed ID: 2177997
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
Darvish-Damavandi M; Nikfar S; Abdollahi M
World J Gastroenterol; 2010 Feb; 16(5):547-53. PubMed ID: 20128021
[TBL] [Abstract][Full Text] [Related]
15. Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea.
Washington N; Ridley P; Thomas C; Spiller RC; Watts PJ; Wilson CG
Aliment Pharmacol Ther; 1998 Jun; 12(6):583-8. PubMed ID: 9678820
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients.
Bouchoucha M; Faye A; Devroede G; Arsac M
Biomed Pharmacother; 2000 Aug; 54(7):381-7. PubMed ID: 10989977
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome.
Kruis W; Weinzierl M; Schüssler P; Holl J
Digestion; 1986; 34(3):196-201. PubMed ID: 3019810
[TBL] [Abstract][Full Text] [Related]
18. [Current approaches to the diagnosis and treatment of irritable bowel syndrome].
Kharchenko NV; Chernenko VV
Lik Sprava; 2001; (5-6):168-71. PubMed ID: 11881362
[TBL] [Abstract][Full Text] [Related]
19. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome.
Simrén M; Abrahamsson H; Björnsson ES
Gut; 2001 Jan; 48(1):20-7. PubMed ID: 11115818
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China.
Hou X; Chen S; Zhang Y; Sha W; Yu X; Elsawah H; Afifi AF; El-Khayat HR; Nouh A; Hassan MF; Fatah AA; Rucker Joerg I; Sánchez Núñez JM; Osthoff Rueda R; Jurkowska G; Walczak M; Malecka-Panas E; Linke K; Hartleb M; Janssen-van Solingen G
Clin Drug Investig; 2014 Nov; 34(11):783-93. PubMed ID: 25258162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
